Literature DB >> 2715888

Incidence and causes of sepsis in glucose-6-phosphate dehydrogenase-deficient newborn infants.

Y K Abu-Osba1, A A Mallouh, R W Hann.   

Abstract

To determine the susceptibility to sepsis in newborn infants deficient in glucose-6-phosphate dehydrogenase (G6PD), we screened 33,943 Saudi Arab infants. Deficiency of G6PD was found in 18%. Sepsis was determined by the presence of clinical signs of sepsis and confirmed by positive blood cultures. Sepsis was documented in 75 infants (2.2/1000). The incidence of sepsis was significantly higher in 6138 G6PD-deficient infants (3.4/1000) than in the 27,805 with normal G6PD activity (1.9/1000; p less than 0.02). The incidence of catalase-positive organism sepsis was higher in G6PD-deficient infants (2.9/1000) compared with those with normal G6PD activity (1/1000; p less than 0.0002), whereas the incidence of catalase-negative organism sepsis did not differ (p less than 0.2). Deficiency of G6PD was more common in infants with late sepsis (46%) than in those with early sepsis (21%) and in all infants screened (18%) (p less than 0.03 and p less than 0.001, respectively). We conclude that neonates with G6PD deficiency are more susceptible to late sepsis and to infection with catalase-positive organisms. The exact mechanism for the increased susceptibility is not clear, but a partial explanation could be lack of leukocyte bactericidal activity associated with G6PD deficiency, and an increased susceptibility to infection caused by hyperferremia resulting from lysis of G6PD-deficient erythrocytes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2715888     DOI: 10.1016/s0022-3476(89)80131-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  8 in total

Review 1.  Prevention of Kernicterus in South Asia: role of neonatal G6PD deficiency and its identification.

Authors:  Yassar H Arain; Vinod K Bhutani
Journal:  Indian J Pediatr       Date:  2014-04-26       Impact factor: 1.967

2.  Endotoxemia down-regulates bone marrow lymphopoiesis but stimulates myelopoiesis: the effect of G6PD deficiency.

Authors:  Rachna Chandra; Erika Villanueva; Eleonora Feketova; George W Machiedo; György Haskó; Edwin A Deitch; Zoltán Spolarics
Journal:  J Leukoc Biol       Date:  2008-03-19       Impact factor: 4.962

3.  How We Manage Invasive Fungal Disease in Acute Myeloid Leukemia Patients with Glucose 6 Dehydrogenase Deficiency.

Authors:  Marco Sanna; Giovanni Caocci; Giorgio La Nasa
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-08-14       Impact factor: 2.576

4.  Glucose 6-phosphate dehydrogenase knockdown enhances IL-8 expression in HepG2 cells via oxidative stress and NF-κB signaling pathway.

Authors:  Hung-Chi Yang; Mei-Ling Cheng; Yi-Syuan Hua; Yi-Hsuan Wu; Hsin-Ru Lin; Hui-Ya Liu; Hung-Yao Ho; Daniel Tsun-Yee Chiu
Journal:  J Inflamm (Lond)       Date:  2015-04-24       Impact factor: 4.981

5.  Prevalence of G6PD Deficiency in Neonatal Sepsis in Iran.

Authors:  Soheila Zareifar; Narjes Pishva; Mohamadreza Farahmandfar; Shahab Benaei; Nader Cohan
Journal:  Iran J Pediatr       Date:  2013-09-15       Impact factor: 0.364

6.  Infections in G6PD-Deficient Hospitalized Patients-Prevalence, Risk Factors, and Related Mortality.

Authors:  Diaa Alrahmany; Ahmed F Omar; Salima R S Al-Maqbali; Gehan Harb; Islam M Ghazi
Journal:  Antibiotics (Basel)       Date:  2022-07-12

7.  Higher infection of dengue virus serotype 2 in human monocytes of patients with G6PD deficiency.

Authors:  Yuan-Chang Chao; Ching-Shan Huang; Chun-Nan Lee; Sui-Yuan Chang; Chwan-Chuen King; Chuan-Liang Kao
Journal:  PLoS One       Date:  2008-02-13       Impact factor: 3.240

8.  Dengue virus type 2 (DENV2)-induced oxidative responses in monocytes from glucose-6-phosphate dehydrogenase (G6PD)-deficient and G6PD normal subjects.

Authors:  Abdullah Ahmed Al-Alimi; Syed A Ali; Faisal Muti Al-Hassan; Fauziah Mohd Idris; Sin-Yeang Teow; Narazah Mohd Yusoff
Journal:  PLoS Negl Trop Dis       Date:  2014-03-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.